Literature DB >> 21028903

Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect.

Jing Sun1, Arik Dahan, Zachary F Walls, Longsheng Lai, Kyung-Dall Lee, Gordon L Amidon.   

Abstract

Human valacyclovirase (hVACVase) is a prodrug-activating enzyme for amino acid prodrugs including the antiviral drugs valacyclovir and valganciclovir. In hVACVase-catalyzed reactions, the leaving group of the substrate corresponds to the drug moiety of the prodrug, making the leaving group effect essential for the rational design of new prodrugs targeting hVACVase activation. In this study, a series of valine esters, phenylalanine esters, and a valine amide were characterized for the effect of the leaving group on the efficiency of hVACVase-mediated prodrug activation. Except for phenylalanine methyl and ethyl esters, all of the ester substrates exhibited a relatively high specificity constant (k(cat)/K(m)), ranging from 850 to 9490 mM(-1)·s(-1). The valine amide Val-3-APG exhibited significantly higher K(m) and lower k(cat) values compared to the corresponding ester Val-3-HPG, indicating poor specificity for hVACVase. In conclusion, the substrate leaving group has been shown to affect both binding and specific activity of hVACVase-catalyzed activation. It is proposed that hVACVase is an ideal target for α-amino acid ester prodrugs with relatively labile leaving groups while it is relatively inactivate toward amide prodrugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21028903      PMCID: PMC2997884          DOI: 10.1021/mp100300k

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  14 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Lessons learned from marketed and investigational prodrugs.

Authors:  Peter Ettmayer; Gordon L Amidon; Bernd Clement; Bernard Testa
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

3.  Catalytic properties of an unspecific carboxylesterase (E1) from rat-liver microsomes.

Authors:  R Arndt; K Krisch
Journal:  Eur J Biochem       Date:  1973-07-02

4.  A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.

Authors:  Insook Kim; Xueqin Song; Balvinder S Vig; Sachin Mittal; Ho-Chul Shin; Philip J Lorenzi; Gordon L Amidon
Journal:  Mol Pharm       Date:  2004 Mar-Apr       Impact factor: 4.939

Review 5.  Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.

Authors:  Erik De Clercq; Hugh J Field
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

6.  Nucleoside ester prodrug substrate specificity of liver carboxylesterase.

Authors:  Christopher P Landowski; Philip L Lorenzi; Xueqin Song; Gordon L Amidon
Journal:  J Pharmacol Exp Ther       Date:  2005-10-13       Impact factor: 4.030

7.  Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase.

Authors:  Insook Kim; Xiao-Yan Chu; Seonyoung Kim; Chester J Provoda; Kyung-Dall Lee; Gordon L Amidon
Journal:  J Biol Chem       Date:  2003-05-05       Impact factor: 5.157

8.  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.

Authors:  Jing Sun; Arik Dahan; Gordon L Amidon
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

Review 9.  Enzyme-catalyzed activation of anticancer prodrugs.

Authors:  Martijn Rooseboom; Jan N M Commandeur; Nico P E Vermeulen
Journal:  Pharmacol Rev       Date:  2004-03       Impact factor: 25.468

Review 10.  Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.

Authors:  Jim Zhen Wu; Chin-chung Lin; Zhi Hong
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

View more
  5 in total

1.  Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis.

Authors:  Wenhui Tao; Dongyang Zhao; Mengchi Sun; Meng Li; Xiangyu Zhang; Zhonggui He; Yinghua Sun; Jin Sun
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

2.  Synthesis and characterization of valyloxy methoxy luciferin for the detection of valacyclovirase and peptide transporter.

Authors:  Zachary F Walls; Sheeba Varghese Gupta; Gordon L Amidon; Kyung-Dall Lee
Journal:  Bioorg Med Chem Lett       Date:  2014-09-16       Impact factor: 2.823

3.  Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease.

Authors:  Arik Dahan; Milica Markovic; Shahar Keinan; Igor Kurnikov; Aaron Aponick; Ellen M Zimmermann; Shimon Ben-Shabat
Journal:  J Comput Aided Mol Des       Date:  2017-11-03       Impact factor: 3.686

Review 4.  Computational Simulations to Guide Enzyme-Mediated Prodrug Activation.

Authors:  Milica Markovic; Shimon Ben-Shabat; Arik Dahan
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

Review 5.  Prodrug Therapies for Infectious and Neurodegenerative Diseases.

Authors:  Milica Markovic; Suyash Deodhar; Jatin Machhi; Pravin Yeapuri; Maamoon Saleh; Benson J Edagwa; Rodney Lee Mosley; Howard E Gendelman
Journal:  Pharmaceutics       Date:  2022-02-26       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.